Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 203

The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.

In Vivo Epigenetic CRISPR Screen Identifies Asf1a as an Immunotherapeutic Target in Kras -Mutant Lung Adenocarcinoma

Open access
Li, Fei, Huang, Qingyuan, Luster, Troy A., Hu, Hai, Zhang, Hua, Ng, Wai-Lung, Khodadadi-Jamayran, Alireza, Wang, Wei, Chen, Ting, Deng, Jiehui, Ranieri, Michela, Fang, Zhaoyuan, Pyon, Val, Dowling, Catríona M., Bagdatlioglu, Ece, Almonte, Christina, Labbe, Kristen, Silver, Heather, Rabin, Alexandra R., Jani, Kandarp, Tsirigos, Aristotelis, Papagiannakopoulos, Thales, Hammerman, Peter S., Velcheti, Vamsidhar, Freeman, Gordon J., Qi, Jun, Miller, George, Wong, Kwok-Kin · 2020 · Cancer Discovery

Abstract

Despite substantial progress in lung cancer immunotherapy, the overall response rate in patients with KRAS-mutant lung adenocarcinoma (LUAD) remains low. Combining standard immunotherapy with adjuvant approaches that enhance adaptive immune responses—such as epigenetic modulation of antitumor immunity—is therefore an attractive strategy. To identify epigenetic regulators of tumor immunity, we constructed an epigenetic-focused single guide RNA library and performed an in vivo CRISPR screen in a KrasG12D/Trp53−/− LUAD model. Our data showed that loss of the histone chaperone Asf1a in tumor cells sensitizes tumors to anti–PD-1 treatment. Mechanistic studies revealed that tumor cell–intrinsic Asf1a deficiency induced immunogenic macrophage differentiation in the tumor microenvironment by upregulating GM-CSF expression and potentiated T-cell activation in combination with anti–PD-1. Our results provide a rationale for a novel combination therapy consisting of ASF1A inhibition and anti–PD-1 immunotherapy. Significance: Using an in vivo epigenetic CRISPR screen, we identified Asf1a as a critical regulator of LUAD sensitivity to anti–PD-1 therapy. Asf1a deficiency synergized with anti–PD-1 immunotherapy by promoting M1-like macrophage polarization and T-cell activation. Thus, we provide a new immunotherapeutic strategy for this subtype of patients with LUAD. See related commentary by Menzel and Black, p. 179. This article is highlighted in the In This Issue feature, p. 161

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/2159-8290.cd-19-0780

Cites

39 of 39 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 39 references

Cited by

See all 203

Metadata

Authors
Li, F., Huang, Q., Luster, T. A., Hu, H., Zhang, H., Ng, W.-L., Khodadadi-Jamayran, A., Wang, W., Chen, T., Deng, J., Ranieri, M., Fang, Z., Pyon, V., Dowling, C. M., Bagdatlioglu, E., Almonte, C., Labbe, K., Silver, H., Rabin, A. R., Jani, K., Tsirigos, A., Papagiannakopoulos, T., Hammerman, P. S., Velcheti, V., Freeman, G. J., Qi, J., Miller, G., & Wong, K.-K.
Venue
Cancer Discovery
Published
2020-02-01
Volume
10
Issue
2
Pages
270-287
ISSN
  • 2159-8274 (ISSN-L)
  • 2159-8290
OpenAlex
W2990393399
Cited by
203
References
39
FWCI
10.88
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: In Vivo Epigenetic CRISPR Screen Identifies Asf1a as an Immunotherapeutic Target in Kras -Mutant Lung Adenocarcinoma. https://app.cochat.ai/papers/10.1158/2159-8290.cd-19-0780
The paper
Li, F., Huang, Q., Luster, T. A., Hu, H., Zhang, H., Ng, W.-L., Khodadadi-Jamayran, A., Wang, W., Chen, T., Deng, J., Ranieri, M., Fang, Z., Pyon, V., Dowling, C. M., Bagdatlioglu, E., Almonte, C., Labbe, K., Silver, H., Rabin, A. R., . . . Wong, K.-K. (2020). In Vivo Epigenetic CRISPR Screen Identifies Asf1a as an Immunotherapeutic Target in Kras -Mutant Lung Adenocarcinoma. Cancer Discovery. https://doi.org/10.1158/2159-8290.cd-19-0780

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.